Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors

Renata Boldrini, Maria Debora De Pasquale, Ombretta Melaiu, Marco Chierici, Giuseppe Jurman, Maria Chiara Benedetti, Nunzio C Salfi, Aurora Castellano, Paola Collini, Cesare Furlanello, Vito Pistoia, Loredana Cifaldi, Monica Terenziani, Doriana Fruci

Research output: Contribution to journalArticle

Abstract

Although pediatric malignant extracranial germ-cell tumors (meGCTs) are among the most chemosensitive solid tumors, a group of patients relapse and die of disease. To identify new markers predicting clinical outcome, we examined the prognostic relevance of tumor-infiltrating T lymphocytes (TILs) and the expression of PD-1 and PD-L1 in a cohort of pediatric meGCTs by in situ immunohistochemistry. MeGCTs were variously infiltrated by T cell-subtypes according to the tumor subtype, tumor location and age at diagnosis. We distinguished three different phenotypes: i) tumors not infiltrated by T cells (immature teratomas and half of the yolk sac tumors), ii) tumors highly infiltrated by CD8+ T cells expressing PD-1, which identifies activated tumor-reactive T cells (seminomas and dysgerminomas), iii) tumors highly infiltrated by CD8+ T cells within an immunosuppressive tumor microenvironment characterized by CD4+FOXP3+ Treg cells and PD-L1-expressing tumor cells (embryonal carcinomas, choriocarcinomas and the remaining yolk sac tumors). Tumor subtypes belonging mixed meGCTs were variously infiltrated, suggesting the coexistence of multiple immune microenvironments either facilitating or precluding the entry of T cells. These findings support the hypothesis that TILs influence the development of meGCTs and might be of clinical relevance to improve risk stratification and the treatment of pediatric patients.

Original languageEnglish
Pages (from-to)e1542245
JournalOncoImmunology
Volume8
Issue number2
DOIs
Publication statusPublished - 2019

Fingerprint

Germ Cell and Embryonal Neoplasms
T-Lymphocytes
Neoplasms
Endodermal Sinus Tumor
Tumor-Infiltrating Lymphocytes
Pediatrics
Dysgerminoma
Embryonal Carcinoma Stem Cells
Seminoma
Choriocarcinoma
Tumor Microenvironment
Teratoma
Regulatory T-Lymphocytes
Immunosuppressive Agents
Biomarkers
Immunohistochemistry
Phenotype
Recurrence

Cite this

Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors. / Boldrini, Renata; De Pasquale, Maria Debora; Melaiu, Ombretta; Chierici, Marco; Jurman, Giuseppe; Benedetti, Maria Chiara; Salfi, Nunzio C; Castellano, Aurora; Collini, Paola; Furlanello, Cesare; Pistoia, Vito; Cifaldi, Loredana; Terenziani, Monica; Fruci, Doriana.

In: OncoImmunology, Vol. 8, No. 2, 2019, p. e1542245.

Research output: Contribution to journalArticle

@article{b7214e31ce2b4e09a75ccabf312c1969,
title = "Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors",
abstract = "Although pediatric malignant extracranial germ-cell tumors (meGCTs) are among the most chemosensitive solid tumors, a group of patients relapse and die of disease. To identify new markers predicting clinical outcome, we examined the prognostic relevance of tumor-infiltrating T lymphocytes (TILs) and the expression of PD-1 and PD-L1 in a cohort of pediatric meGCTs by in situ immunohistochemistry. MeGCTs were variously infiltrated by T cell-subtypes according to the tumor subtype, tumor location and age at diagnosis. We distinguished three different phenotypes: i) tumors not infiltrated by T cells (immature teratomas and half of the yolk sac tumors), ii) tumors highly infiltrated by CD8+ T cells expressing PD-1, which identifies activated tumor-reactive T cells (seminomas and dysgerminomas), iii) tumors highly infiltrated by CD8+ T cells within an immunosuppressive tumor microenvironment characterized by CD4+FOXP3+ Treg cells and PD-L1-expressing tumor cells (embryonal carcinomas, choriocarcinomas and the remaining yolk sac tumors). Tumor subtypes belonging mixed meGCTs were variously infiltrated, suggesting the coexistence of multiple immune microenvironments either facilitating or precluding the entry of T cells. These findings support the hypothesis that TILs influence the development of meGCTs and might be of clinical relevance to improve risk stratification and the treatment of pediatric patients.",
author = "Renata Boldrini and {De Pasquale}, {Maria Debora} and Ombretta Melaiu and Marco Chierici and Giuseppe Jurman and Benedetti, {Maria Chiara} and Salfi, {Nunzio C} and Aurora Castellano and Paola Collini and Cesare Furlanello and Vito Pistoia and Loredana Cifaldi and Monica Terenziani and Doriana Fruci",
year = "2019",
doi = "10.1080/2162402X.2018.1542245",
language = "English",
volume = "8",
pages = "e1542245",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "2",

}

TY - JOUR

T1 - Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors

AU - Boldrini, Renata

AU - De Pasquale, Maria Debora

AU - Melaiu, Ombretta

AU - Chierici, Marco

AU - Jurman, Giuseppe

AU - Benedetti, Maria Chiara

AU - Salfi, Nunzio C

AU - Castellano, Aurora

AU - Collini, Paola

AU - Furlanello, Cesare

AU - Pistoia, Vito

AU - Cifaldi, Loredana

AU - Terenziani, Monica

AU - Fruci, Doriana

PY - 2019

Y1 - 2019

N2 - Although pediatric malignant extracranial germ-cell tumors (meGCTs) are among the most chemosensitive solid tumors, a group of patients relapse and die of disease. To identify new markers predicting clinical outcome, we examined the prognostic relevance of tumor-infiltrating T lymphocytes (TILs) and the expression of PD-1 and PD-L1 in a cohort of pediatric meGCTs by in situ immunohistochemistry. MeGCTs were variously infiltrated by T cell-subtypes according to the tumor subtype, tumor location and age at diagnosis. We distinguished three different phenotypes: i) tumors not infiltrated by T cells (immature teratomas and half of the yolk sac tumors), ii) tumors highly infiltrated by CD8+ T cells expressing PD-1, which identifies activated tumor-reactive T cells (seminomas and dysgerminomas), iii) tumors highly infiltrated by CD8+ T cells within an immunosuppressive tumor microenvironment characterized by CD4+FOXP3+ Treg cells and PD-L1-expressing tumor cells (embryonal carcinomas, choriocarcinomas and the remaining yolk sac tumors). Tumor subtypes belonging mixed meGCTs were variously infiltrated, suggesting the coexistence of multiple immune microenvironments either facilitating or precluding the entry of T cells. These findings support the hypothesis that TILs influence the development of meGCTs and might be of clinical relevance to improve risk stratification and the treatment of pediatric patients.

AB - Although pediatric malignant extracranial germ-cell tumors (meGCTs) are among the most chemosensitive solid tumors, a group of patients relapse and die of disease. To identify new markers predicting clinical outcome, we examined the prognostic relevance of tumor-infiltrating T lymphocytes (TILs) and the expression of PD-1 and PD-L1 in a cohort of pediatric meGCTs by in situ immunohistochemistry. MeGCTs were variously infiltrated by T cell-subtypes according to the tumor subtype, tumor location and age at diagnosis. We distinguished three different phenotypes: i) tumors not infiltrated by T cells (immature teratomas and half of the yolk sac tumors), ii) tumors highly infiltrated by CD8+ T cells expressing PD-1, which identifies activated tumor-reactive T cells (seminomas and dysgerminomas), iii) tumors highly infiltrated by CD8+ T cells within an immunosuppressive tumor microenvironment characterized by CD4+FOXP3+ Treg cells and PD-L1-expressing tumor cells (embryonal carcinomas, choriocarcinomas and the remaining yolk sac tumors). Tumor subtypes belonging mixed meGCTs were variously infiltrated, suggesting the coexistence of multiple immune microenvironments either facilitating or precluding the entry of T cells. These findings support the hypothesis that TILs influence the development of meGCTs and might be of clinical relevance to improve risk stratification and the treatment of pediatric patients.

U2 - 10.1080/2162402X.2018.1542245

DO - 10.1080/2162402X.2018.1542245

M3 - Article

C2 - 30713803

VL - 8

SP - e1542245

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 2

ER -